the Efficacy and Safety of Ginsenoside Rg3 Capsule in Prevention of Postoperative Recurrence of Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Using the subject with hepatocellular carcinoma in the conventional therapy to evaluate the
efficacy and safety of ginsenoside Rg3 (20mg BID) and placebo in prevention and treatment of
postoperative recurrence of liver cancer,respectively
Phase:
N/A
Details
Lead Sponsor:
ShenFeng
Collaborators:
First Affiliated Hospital of Fujian Medical University First Affiliated Hospital of Harbin Medical University Huazhong University of Science and Technology Shanghai Zhongshan Hospital Sun Yat-sen University